title: Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.
authors.affiliation: Department of Medicine, Memorial-Sloan Kettering Cancer Center, New York, NY. Electronic address: mdf9007@nyp.org.
authors.forename: Marissa D
authors.initials: MD
authors.lastname: Friedman
authors.affiliation: Department of Dermatology, Memorial-Sloan Kettering Cancer Center, New York, NY.
authors.forename: Mario
authors.initials: M
authors.lastname: Lacouture
authors.affiliation: Department of Medicine, Memorial-Sloan Kettering Cancer Center, New York, NY.
authors.forename: Chau
authors.initials: C
authors.lastname: Dang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003875:Drug Eruptions / Q000453:epidemiology / Q000473:pathology; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects; D000068878:Trastuzumab / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011799:Quinazolines; D000077341:Lapatinib; D000068878:Trastuzumab; D017239:Paclitaxel
keywords: Adjuvant; HER2+; Lapatinib; Rash; Toxicity